Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Ian Schofield

Edinburgh, U.K
Ian Schofield has been writing on issues affecting the pharmaceutical and biotech industry since the mid-1980s, specialising in EU and global policy and regulatory affairs.  As well as writing, editing and commissioning articles for Pharma Intelligence, Ian works for the Ask the Analyst service, providing tailor-made answers to questions posed directly by clients. He has a degree in modern languages from the University of Bath. Outside the realm of work, Ian plays guitar in a traditional music group and also enjoys a touch of cycling and gardening. He lives by the seaside about three miles from the centre of Edinburgh.
Advertisement
Set Alert for Articles By Ian Schofield

Latest From Ian Schofield

Canada To Have Patent Term Extensions Soon – And An Export Waiver

A bill implementing the provisions of the EU-Canada CETA trade deal is expected to be approved soon, bringing a new Certificate of Supplementary Protection together with an export manufacturing waiver, and some changes to the patent litigation system.

Intellectual Property Generic Drugs

EC To Consult On Ways To Boost Generics & Biosimilars Industry, Introduce EU-wide SPC

A new package of measures from the European Commission will introduce an SPC export manufacturing waiver to help improve the competitiveness of Europe’s generics and biosimilars industry, while originator companies should benefit from steps to smooth out the rules on the “Bolar” research exemption and implement an EU-wide SPC.

Manufacturing Legal Issues

Malta Bids For EMA, Citing Quality Of Life, Healthcare, And Small Pharma Industry

Malta has joined the ever-growing number of countries wanting to host the European Medicines Agency when it relocates from the UK post-Brexit. The European Commission has said new “technical issues” have been raised that will need to be addressed, and industry bodies have outlined the criteria they say need to be met by the future host country.

Malta Brexit

Czech President Signs Law Limiting Medicine Re-Exports – But Will It Work?

An amendment to the Medicines Act designed to limit distributors’ ability to parallel export medicines to higher priced EU markets has been signed, but some lawyers argue it might not be fit for purpose.

Distribution Czech Republic

Germany Heads For Ratification Of Unified Patent Court; Spanish MPs Push For Membership

Germany, one of three countries whose signature is vital if the new Unified Patent Court is to get up and running, has taken another step towards ratification of the UPC agreement, while the Spanish parliament has approved a motion urging the government to drop its opposition to Spain’s becoming part of the new system.

Intellectual Property Germany

Health NGO Urges Future Dutch Govt To Act On High Drug Prices

As the Dutch elections draw near, the civil society body Health Action International has launched a campaign calling on a future government to tackle what it calls “soaring” drug prices. The move follows the adoption of a European Parliament Resolution demanding a better balance between public health imperatives and industry interests.

Pricing Debate Europe
See All
Advertisement
UsernamePublicRestriction

Register